KR102240865B9 - Pde4 억제제의 제조 방법 - Google Patents

Pde4 억제제의 제조 방법

Info

Publication number
KR102240865B9
KR102240865B9 KR1020167010773A KR20167010773A KR102240865B9 KR 102240865 B9 KR102240865 B9 KR 102240865B9 KR 1020167010773 A KR1020167010773 A KR 1020167010773A KR 20167010773 A KR20167010773 A KR 20167010773A KR 102240865 B9 KR102240865 B9 KR 102240865B9
Authority
KR
South Korea
Prior art keywords
pde4
preparation
inhibitor
pde4 inhibitor
pde4 process
Prior art date
Application number
KR1020167010773A
Other languages
English (en)
Other versions
KR20160072127A (ko
KR102240865B1 (ko
Inventor
알레산드로 팔키
에밀리오 루테로
에마누엘레 페라리
파우스토 피베티
로코 부솔라티
에도아르도 마리아니
오르솔라 베키
에르하르트 바페르트
카테리나 벤트리치
Original Assignee
키에시 파르마슈티시 엣스. 피. 에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49385193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102240865(B9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 키에시 파르마슈티시 엣스. 피. 에이. filed Critical 키에시 파르마슈티시 엣스. 피. 에이.
Priority to KR1020217004799A priority Critical patent/KR102287598B1/ko
Priority to KR1020217004798A priority patent/KR102287596B1/ko
Publication of KR20160072127A publication Critical patent/KR20160072127A/ko
Application granted granted Critical
Publication of KR102240865B1 publication Critical patent/KR102240865B1/ko
Publication of KR102240865B9 publication Critical patent/KR102240865B9/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/59—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020167010773A 2013-10-22 2014-10-17 Pde4 억제제의 제조 방법 KR102240865B1 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020217004799A KR102287598B1 (ko) 2013-10-22 2014-10-17 Pde4 억제제의 제조 방법
KR1020217004798A KR102287596B1 (ko) 2013-10-22 2014-10-17 Pde4 억제제의 제조 방법

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13189784 2013-10-22
EP13189784.5 2013-10-22

Related Child Applications (2)

Application Number Title Priority Date Filing Date
KR1020217004798A Division KR102287596B1 (ko) 2013-10-22 2014-10-17 Pde4 억제제의 제조 방법
KR1020217004799A Division KR102287598B1 (ko) 2013-10-22 2014-10-17 Pde4 억제제의 제조 방법

Publications (3)

Publication Number Publication Date
KR20160072127A KR20160072127A (ko) 2016-06-22
KR102240865B1 KR102240865B1 (ko) 2021-04-16
KR102240865B9 true KR102240865B9 (ko) 2021-12-13

Family

ID=49385193

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020217004799A KR102287598B1 (ko) 2013-10-22 2014-10-17 Pde4 억제제의 제조 방법
KR1020217004798A KR102287596B1 (ko) 2013-10-22 2014-10-17 Pde4 억제제의 제조 방법
KR1020167010773A KR102240865B1 (ko) 2013-10-22 2014-10-17 Pde4 억제제의 제조 방법

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020217004799A KR102287598B1 (ko) 2013-10-22 2014-10-17 Pde4 억제제의 제조 방법
KR1020217004798A KR102287596B1 (ko) 2013-10-22 2014-10-17 Pde4 억제제의 제조 방법

Country Status (30)

Country Link
US (7) US9434691B2 (ko)
EP (5) EP3798209A1 (ko)
JP (5) JP6458957B2 (ko)
KR (3) KR102287598B1 (ko)
CN (3) CN114621139A (ko)
AR (4) AR098128A1 (ko)
AU (1) AU2014339136C1 (ko)
BR (1) BR112016008161B1 (ko)
CA (3) CA3115587A1 (ko)
CY (1) CY1123811T1 (ko)
DK (3) DK3060551T3 (ko)
ES (2) ES2857629T3 (ko)
FI (1) FI3587400T3 (ko)
HK (1) HK1223926A1 (ko)
HR (2) HRP20192152T1 (ko)
HU (2) HUE046637T2 (ko)
IL (4) IL285532B2 (ko)
LT (2) LT3293176T (ko)
MX (4) MX370104B (ko)
MY (1) MY182559A (ko)
PH (2) PH12016500737B1 (ko)
PL (2) PL3060551T3 (ko)
PT (2) PT3293176T (ko)
RS (2) RS65452B1 (ko)
RU (1) RU2682660C9 (ko)
SG (4) SG11201603130TA (ko)
SI (3) SI3587400T1 (ko)
TW (3) TWI720803B (ko)
UA (2) UA127453C2 (ko)
WO (1) WO2015059050A1 (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2600830T (lt) 2010-08-03 2018-04-10 Chiesi Farmaceutici S.P.A. Sausų miltelių kompozicija, apimanti fosfodiesterazės inhibitorių
DK3060551T3 (da) 2013-10-22 2019-10-28 Chiesi Farm Spa Fremgangsmåde til fremstilling af en PDE4-hæmmer
US20190275022A1 (en) * 2016-07-20 2019-09-12 Allergan, Inc. Methods, compositions, and compounds for treatment of dermatological and ocular conditions
JP7361584B2 (ja) * 2018-12-19 2023-10-16 高砂香料工業株式会社 アミドの還元によるアミンの製造方法
US11149615B2 (en) 2018-12-25 2021-10-19 Toyota Jidosha Kabushiki Kaisha Control device for internal combustion engine
JP6780763B2 (ja) 2018-12-25 2020-11-04 トヨタ自動車株式会社 内燃機関の制御装置
CN111808029A (zh) * 2020-08-31 2020-10-23 兰晟生物医药(苏州)有限公司 一种pde4抑制剂氯比普兰的制备方法
WO2023117985A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
WO2023208982A1 (en) 2022-04-27 2023-11-02 Chiesi Farmaceutici S.P.A. Crystal form of a pde4 inhibitor
CN115304542B (zh) * 2022-07-18 2024-02-02 湖南华纳大药厂手性药物有限公司 一种3-羟基吡啶的合成工艺
WO2024027901A1 (en) 2022-08-02 2024-02-08 Chiesi Farmaceutici S.P.A. Predictive biomarker of clinical response to a pde4 inhibitor
WO2024062005A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
WO2024062006A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
WO2024062007A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935978A (en) * 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
MXPA02012678A (es) * 2000-03-30 2004-09-10 Chirotech Technology Ltd Complejos de rutenio-difosfina y su uso como catalizadores.
EP1670742A1 (en) 2003-09-12 2006-06-21 Ranbaxy Laboratories Limited Process for the preparation of roflumilast
PL1740593T3 (pl) 2004-04-19 2016-09-30 Sposoby wytwarzania wodorosiarczanu klopidogrelu w formie polimorficznej I
PT1749001E (pt) * 2004-04-29 2010-05-31 Aventis Pharma Inc 3-piperidinilisocroman-5-oles como agonistas da dopamina
KR20070079278A (ko) 2006-02-01 2007-08-06 삼성전자주식회사 수신자 제한 시스템을 이용하는 디지털 멀티미디어시스템에서 수신기의 채널 전환 시간 단축 장치 및 방법
ATE496029T1 (de) 2006-07-14 2011-02-15 Chiesi Farma Spa Derivate von 1-phenyl-2-pyridinylalkylenalkohole als phosphodiesteraseinhibitoren
RU2493149C2 (ru) * 2006-12-22 2013-09-20 Лео Фарма А/С Замещенные метилфенилкетоны, пригодные для использования в качестве ингибиторов pde4
EP2022783A1 (en) * 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
US20100015430A1 (en) 2008-07-16 2010-01-21 Outlast Technologies, Inc. Heat Regulating Article With Moisture Enhanced Temperature Control
EP2216327A1 (en) * 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
CN102939280B (zh) 2010-06-14 2014-11-19 奇斯药制品公司 格隆氯铵的晶型
LT2600830T (lt) * 2010-08-03 2018-04-10 Chiesi Farmaceutici S.P.A. Sausų miltelių kompozicija, apimanti fosfodiesterazės inhibitorių
CA2807406C (en) 2010-08-03 2018-12-11 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
WO2012071336A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Salts and crystalline forms of an apoptosis-inducing agent
CN103827088B (zh) * 2011-09-26 2017-10-13 奇斯药制品公司 作为磷酸二酯酶抑制剂的1‑苯基‑2‑吡啶基烷基醇的衍生物
WO2013087749A1 (en) 2011-12-16 2013-06-20 Chiesi Farmaceutici S.P.A. Potentiation induced by pde4 inhibitors in the treatment of leukemia
CA2893628C (en) * 2012-12-05 2021-11-30 Chiesi Farmaceutici S.P.A. 1-phenyl-2-pyridinyl alkyl alcohol derivatives as phosphodiesterase inhibitors
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
DK3060551T3 (da) * 2013-10-22 2019-10-28 Chiesi Farm Spa Fremgangsmåde til fremstilling af en PDE4-hæmmer
KR101591785B1 (ko) 2013-12-24 2016-02-04 주식회사 투게더 데이터 입력 장치, 이를 이용한 데이터 전송 시스템 및 방법
BR112020012972A2 (pt) * 2017-12-28 2020-11-24 Chiesi Farmaceutici S.P.A. uso de derivados de álcool 1-fenil-2-piridinil alquílico para tratar fibrose cística
WO2023117985A1 (en) * 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity

Also Published As

Publication number Publication date
TW201605804A (zh) 2016-02-16
EP3060551B1 (en) 2019-09-18
IL285532B2 (en) 2024-03-01
DK3293176T3 (da) 2021-02-15
JP2017505752A (ja) 2017-02-23
US9434691B2 (en) 2016-09-06
EP3587400B1 (en) 2024-03-20
UA121853C2 (uk) 2020-08-10
AR098128A1 (es) 2016-05-04
KR102287598B1 (ko) 2021-08-11
SI3587400T1 (sl) 2024-05-31
ES2759514T3 (es) 2020-05-11
CY1123811T1 (el) 2022-05-27
DK3587400T3 (da) 2024-04-02
BR112016008161A2 (ko) 2017-08-01
IL285532A (en) 2021-09-30
US10323003B2 (en) 2019-06-18
AU2014339136B2 (en) 2018-05-31
SG11201603130TA (en) 2016-05-30
MX370104B (es) 2019-12-02
KR20210021415A (ko) 2021-02-25
EP3293176A1 (en) 2018-03-14
JP2022068321A (ja) 2022-05-09
SG10202112587RA (en) 2021-12-30
PL3293176T3 (pl) 2021-06-28
JP7051970B2 (ja) 2022-04-11
HUE046637T2 (hu) 2020-03-30
CA3115570C (en) 2024-01-30
US20160326117A1 (en) 2016-11-10
US20210040040A1 (en) 2021-02-11
LT3587400T (lt) 2024-04-25
MX2016004834A (es) 2016-07-19
RS65452B1 (sr) 2024-05-31
PH12020500162A1 (en) 2021-08-02
MY182559A (en) 2021-01-25
CN105658629B (zh) 2019-07-16
TW202021952A (zh) 2020-06-16
RU2682660C2 (ru) 2019-03-20
MX2022000036A (es) 2022-07-19
US20240166605A1 (en) 2024-05-23
IL245220A0 (en) 2016-06-30
EP4059921A1 (en) 2022-09-21
CN105658629A (zh) 2016-06-08
PT3060551T (pt) 2019-12-09
CN110256338A (zh) 2019-09-20
IL252834A0 (en) 2017-08-31
UA127453C2 (uk) 2023-08-30
PH12016500737A1 (en) 2016-05-30
US10759761B2 (en) 2020-09-01
EP3587400A2 (en) 2020-01-01
WO2015059050A1 (en) 2015-04-30
RU2016115246A (ru) 2017-11-27
US20150111931A1 (en) 2015-04-23
PT3293176T (pt) 2021-03-03
HUE053112T2 (hu) 2021-06-28
EP3798209A1 (en) 2021-03-31
MX2019014408A (es) 2020-01-27
CA2928242A1 (en) 2015-04-30
TWI651305B (zh) 2019-02-21
IL285532B1 (en) 2023-11-01
SI3293176T1 (sl) 2021-04-30
BR112016008161B1 (pt) 2022-11-29
EP3587400A3 (en) 2020-03-25
CN114621139A (zh) 2022-06-14
HRP20210336T1 (hr) 2021-04-16
SI3060551T1 (sl) 2019-11-29
JP6458957B2 (ja) 2019-01-30
PH12016500737B1 (en) 2016-05-30
CA2928242C (en) 2022-03-15
TW201904945A (zh) 2019-02-01
TWI685486B (zh) 2020-02-21
HRP20192152T1 (hr) 2020-02-21
IL252834B (en) 2021-09-30
KR20160072127A (ko) 2016-06-22
KR102240865B1 (ko) 2021-04-16
AR122183A2 (es) 2022-08-24
MX2022000030A (es) 2022-07-19
LT3293176T (lt) 2021-03-25
EP3060551A1 (en) 2016-08-31
RU2016115246A3 (ko) 2018-06-27
US20220348545A1 (en) 2022-11-03
US11352327B2 (en) 2022-06-07
AU2014339136C1 (en) 2019-10-31
JP2021011494A (ja) 2021-02-04
JP2019038813A (ja) 2019-03-14
AR122182A2 (es) 2022-08-24
IL285528A (en) 2021-09-30
DK3060551T3 (da) 2019-10-28
KR20210021416A (ko) 2021-02-25
US11981639B2 (en) 2024-05-14
ES2857629T3 (es) 2021-09-29
US9890122B2 (en) 2018-02-13
PL3060551T3 (pl) 2020-03-31
US20180118686A1 (en) 2018-05-03
JP7345581B2 (ja) 2023-09-15
EP3293176B1 (en) 2020-12-02
RU2682660C9 (ru) 2019-06-21
IL245220A (en) 2017-06-29
TWI720803B (zh) 2021-03-01
US20190345108A1 (en) 2019-11-14
JP2022071008A (ja) 2022-05-13
HK1223926A1 (zh) 2017-08-11
RS61558B1 (sr) 2021-04-29
FI3587400T3 (fi) 2024-06-20
SG10201903575UA (en) 2019-05-30
CA3115587A1 (en) 2015-04-30
SG10201912852YA (en) 2020-02-27
KR102287596B1 (ko) 2021-08-11
AR118124A2 (es) 2021-09-22
CA3115570A1 (en) 2015-04-30

Similar Documents

Publication Publication Date Title
IL285532A (en) A process for preparing a pde4 inhibitor
GB201317609D0 (en) Inhibitor compounds
EP3020718A4 (en) NOVEL PDE4 INHIBITOR
IL245474A0 (en) Process for the preparation of 5-fluoro-1h-pyrazoles
IL245476B (en) Process for the preparation of 5-fluoro-1h-pyrazoles
IL281072B (en) Processes for the preparation of pyrimidinylcyclopentane compounds
HK1219094A1 (zh) 氟內酯衍生物配製過程
IL229326A (en) Process for making n-iodine-affluent
HUP1600128A2 (en) A new process for the preparation of elvitegravir
IL246188B (en) A process for the preparation of tiacomycin
GB201321328D0 (en) Inhibitor compounds

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
A107 Divisional application of patent
AMND Amendment
E601 Decision to refuse application
AMND Amendment
X701 Decision to grant (after re-examination)
J202 Request for trial for correction [limitation]
J301 Trial decision

Free format text: TRIAL NUMBER: 2021105000041; TRIAL DECISION FOR CORRECTION REQUESTED 20210517

Effective date: 20211126